Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATNF NASDAQ:AVTX NASDAQ:EXOZ NASDAQ:VXRT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATNF180 Life Sciences$3.58+6.5%$1.51$0.66▼$17.75$20.29M0.387.03 million shs812,363 shsAVTXAvalo Therapeutics$8.31+1.3%$5.31$3.39▼$16.00$88.79M0.8235,906 shs186,632 shsEXOZeXoZymes$10.01-0.8%$10.98$8.50▼$23.99$84.39MN/A5,425 shs744 shsVXRTVaxart$0.40+8.7%$0.45$0.26▼$1.07$84.24M1.123.19 million shs1.30 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATNF180 Life Sciences+6.55%+1.70%+347.67%+228.44%+106.94%AVTXAvalo Therapeutics+1.34%+24.77%+74.95%+91.03%-23.34%EXOZeXoZymes-0.79%-0.89%-1.67%-19.98%+1,000,999,900.00%VXRTVaxart+8.99%+9.59%+25.00%-1.72%-34.17%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATNF180 Life Sciences0.5903 of 5 stars0.04.00.00.01.11.70.0AVTXAvalo Therapeutics2.5118 of 5 stars3.53.00.00.00.61.71.3EXOZeXoZymesN/AN/AN/AN/AN/AN/AN/AN/AVXRTVaxart3.4261 of 5 stars3.55.00.00.03.31.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATNF180 Life Sciences 0.00N/AN/AN/AAVTXAvalo Therapeutics 3.00Buy$30.00261.01% UpsideEXOZeXoZymes 0.00N/AN/AN/AVXRTVaxart 3.00Buy$3.00650.00% UpsideCurrent Analyst Ratings BreakdownLatest ATNF, AVTX, VXRT, and EXOZ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/29/2025ATNF180 Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)7/12/2025ATNF180 Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)6/27/2025ATNF180 Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)6/11/2025ATNF180 Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)6/2/2025AVTXAvalo TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$15.005/24/2025ATNF180 Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)5/10/2025ATNF180 Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)(Data available from 8/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATNF180 Life SciencesN/AN/AN/AN/A$0.89 per shareN/AAVTXAvalo Therapeutics$440K204.54N/AN/A$12.80 per share0.65EXOZeXoZymesN/AN/AN/AN/A$1.25 per shareN/AVXRTVaxart$47.40M1.93N/AN/A$0.26 per share1.54Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATNF180 Life Sciences-$6.17M-$15.07N/A∞N/AN/A-141.25%-80.77%8/11/2025 (Estimated)AVTXAvalo Therapeutics-$35.13MN/A0.00N/AN/AN/A111.00%58.88%8/11/2025 (Estimated)EXOZeXoZymes-$5.86MN/A0.00∞N/AN/AN/AN/AN/AVXRTVaxart-$66.95M-$0.27N/AN/AN/A-122.63%-91.89%-38.40%8/14/2025 (Estimated)Latest ATNF, AVTX, VXRT, and EXOZ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025VXRTVaxart-$0.08N/AN/AN/AN/AN/A8/11/2025Q2 2025AVTXAvalo Therapeutics-$1.43N/AN/AN/AN/AN/A7/23/2025Q2 2025ATNF180 Life SciencesN/A-$0.30N/A-$0.30N/AN/A5/15/2025Q1 2025ATNF180 Life SciencesN/A-$0.67N/A-$0.67N/AN/A5/13/2025Q1 2025VXRTVaxart-$0.07-$0.07N/A-$0.07$2.85 million$20.88 million5/12/2025Q1 2025AVTXAvalo Therapeutics-$1.07-$1.25-$0.18-$1.25N/AN/A5/12/2025Q1 2025EXOZeXoZymesN/A-$0.22N/A-$0.22N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATNF180 Life SciencesN/AN/AN/AN/AN/AAVTXAvalo TherapeuticsN/AN/AN/AN/AN/AEXOZeXoZymesN/AN/AN/AN/AN/AVXRTVaxartN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATNF180 Life SciencesN/A0.580.58AVTXAvalo TherapeuticsN/A22.6122.61EXOZeXoZymesN/A6.526.52VXRTVaxartN/A0.640.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATNF180 Life Sciences4.07%AVTXAvalo Therapeutics87.06%EXOZeXoZymesN/AVXRTVaxart18.05%Insider OwnershipCompanyInsider OwnershipATNF180 Life Sciences38.20%AVTXAvalo Therapeutics3.03%EXOZeXoZymes72.41%VXRTVaxart2.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATNF180 Life Sciences76.04 million3.73 millionNo DataAVTXAvalo Therapeutics4010.83 million10.50 millionNot OptionableEXOZeXoZymes298.37 million2.31 millionN/AVXRTVaxart120228.91 million222.37 millionOptionableATNF, AVTX, VXRT, and EXOZ HeadlinesRecent News About These CompaniesVaxart (NASDAQ:VXRT) Stock Price Passes Below 200-Day Moving Average - Here's Why1 hour ago | marketbeat.comVaxart (VXRT) Expected to Announce Earnings on Thursday4 hours ago | marketbeat.comVaxart, Inc. Stock (VXRT) Opinions on Reverse Stock Split ProposalJuly 31, 2025 | quiverquant.comQVaxart (NASDAQ:VXRT) Stock Price Crosses Below 200 Day Moving Average - Here's WhyJuly 29, 2025 | marketbeat.comVaxart Submits Proxy Statement for Reverse Stock Split to Support Resumption of Trading on NasdaqJuly 24, 2025 | globenewswire.comVaxart (NASDAQ:VXRT) Shares Cross Below 200-Day Moving Average - What's Next?July 19, 2025 | marketbeat.comVaxart (NASDAQ:VXRT) Share Price Crosses Below Two Hundred Day Moving Average - Here's What HappenedJuly 11, 2025 | marketbeat.comOTC Markets Group Welcomes Vaxart, Inc. to OTCQXJuly 8, 2025 | financialpost.comFVaxart Announces Preliminary Results of Annual Meeting of StockholdersJune 13, 2025 | globenewswire.comVaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation TechnologyJune 11, 2025 | globenewswire.comVaxart, Inc. to Release Topline Data from Norovirus Phase I Trial on June 11, 2025June 10, 2025 | quiverquant.comQVaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus TrialJune 10, 2025 | globenewswire.comVaxart Announces Adjournment of Annual Meeting of StockholdersJune 2, 2025 | globenewswire.comVaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025May 29, 2025 | globenewswire.comVaxart's Dr. Sean Tucker Calls on Stockholders to Support Reverse Stock Split Proposal by June 1, 2025May 29, 2025 | quiverquant.comQVaxart's Founder and Chief Scientific Officer Provides Video Update to StockholdersMay 29, 2025 | globenewswire.comVaxart Discusses Reverse Stock Split and Capital RaiseMay 28, 2025 | tipranks.comVaxart Answers Additional Frequently Asked Questions from Retail InvestorsMay 28, 2025 | globenewswire.comVaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 TrialMay 27, 2025 | globenewswire.comVaxart Announces Adjournment of Annual Meeting of StockholdersMay 21, 2025 | globenewswire.comVaxart, Inc. Grants Equity Awards to New CFO Jeroen GrasmanMay 20, 2025 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeATNF, AVTX, VXRT, and EXOZ Company Descriptions180 Life Sciences NASDAQ:ATNF$3.58 +0.22 (+6.55%) Closing price 08/6/2025 04:00 PM EasternExtended Trading$3.48 -0.10 (-2.65%) As of 06:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.Avalo Therapeutics NASDAQ:AVTX$8.31 +0.11 (+1.34%) Closing price 08/6/2025 04:00 PM EasternExtended Trading$6.20 -2.11 (-25.39%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.eXoZymes NASDAQ:EXOZ$10.01 -0.08 (-0.79%) As of 08/6/2025 02:31 PM EasterneXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.Vaxart NASDAQ:VXRT$0.40 +0.03 (+8.70%) As of 08/6/2025 03:59 PM EasternVaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Joby Deal Gives Blade New Direction, But Stock Lacks Lift How DigitalOcean's Focus Is Fueling Explosive Growth Disney’s Iger-Led Turnaround Gains Traction Can Celsius Stock Keep Its Momentum Going Any Longer? AMD’s Results Sparked a Sell-Off—But That’s Your Buy Signal Rivian Takes Earnings Hit—R2 Could Be the Stock's 2026 Lifeline Does Broadcom Have a VMware Problem? Goldman Eyes Upside in NTNX RSI Stock Soars 22% On Q2 Blowout—Will PENN Match the Momentum? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
